Publications

BibTex format

@article{Castagnoli:2022:10.1371/journal.pone.0270950,
author = {Castagnoli, F and Doran, S and Lunn, J and Minchom, A and O'Brien, M and Popat, S and Messiou, C and Koh, D-M},
doi = {10.1371/journal.pone.0270950},
journal = {PLoS One},
title = {Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy.},
url = {http://dx.doi.org/10.1371/journal.pone.0270950},
volume = {17},
year = {2022}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - INTRODUCTION: The spleen is a lymphoid organ and we hypothesize that clinical benefit to immunotherapy may present with an increase in splenic volume during treatment. The purpose of this study was to investigate whether changes in splenic volume could be observed in those showing clinical benefit versus those not showing clinical benefit to pembrolizumab treatment in non-small cell lung cancer (NSCLC) patients. MATERIALS AND METHODS: In this study, 70 patients with locally advanced or metastatic NSCLC treated with pembrolizumab; and who underwent baseline CT scan within 2 weeks before treatment and follow-up CT within 3 months after commencing immunotherapy were retrospectively evaluated. The splenic volume on each CT was segmented manually by outlining the splenic contour on every image and the total volume summated. We compared the splenic volume in those achieving a clinical benefit and those not achieving clinical benefit, using non-parametric Wilcoxon signed-rank test. Clinical benefit was defined as stable disease or partial response lasting for greater than 24 weeks. A p-value of <0.05 was considered statistically significant. RESULTS: There were 23 responders and 47 non-responders based on iRECIST criteria and 35 patients with clinical benefit and 35 without clinical benefit. There was no significant difference in the median pre-treatment volume (175 vs 187 cm3, p = 0.34), post-treatment volume (168 vs 167 cm3, p = 0.39) or change in splenic volume (-0.002 vs 0.0002 cm3, p = 0.97) between the two groups. No significant differences were also found between the splenic volume of patients with partial response, stable disease or progressive disease (p>0.017). Moreover, there was no statistically significant difference between progression-free survival and time to disease progression when the splenic volume was categorized as smaller or larger than the median pre-treatment or post-treatment volume (p>0.05). CONCLUSION: No significant differences were ob
AU  - Castagnoli,F
AU  - Doran,S
AU  - Lunn,J
AU  - Minchom,A
AU  - O'Brien,M
AU  - Popat,S
AU  - Messiou,C
AU  - Koh,D-M
DO  - 10.1371/journal.pone.0270950
PY  - 2022///
TI  - Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy.
T2  - PLoS One
UR  - http://dx.doi.org/10.1371/journal.pone.0270950
UR  - https://www.ncbi.nlm.nih.gov/pubmed/35797413
VL  - 17
ER  -

Download

DrSanjayPopat

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)